表紙
市場調査レポート

Silence Therapeutics plc:製品パイプライン分析

Silence Therapeutics Plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 226231
出版日 ページ情報 英文 35 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
Silence Therapeutics plc:製品パイプライン分析 Silence Therapeutics Plc - Product Pipeline Review - 2015
出版日: 2015年09月09日 ページ情報: 英文 35 Pages
概要

Silence Therapeutics plc (旧SR Pharma plc)は、重病治療のためのRNA干渉治療薬の開発と送達に取り組むバイオテクノロジー企業です。同社のパイプライン製品は、膵臓・頭部・頸部の癌や肺疾患の治療に使われています。同社はまた、糖尿病性黄斑浮腫や加齢性黄斑変性、腎移植後臓器機能障害などの治療薬の開発にも取り組んでいます。

当レポートでは、Silence Therapeutics plcにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Silence Therapeutics Plcの基本情報

  • Silence Therapeutics Plcの概要
  • 主要情報
  • 企業情報

Silence Therapeutics Plc:R&Dの概要

  • 主な治療範囲

Silence Therapeutics Plc:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Silence Therapeutics Plc:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Silence Therapeutics Plc:薬剤プロファイル

  • Atu-027
  • Atu-111
  • Atu-112
  • Atu-134
  • 肺動脈高血圧症向けエンドスリン-1阻害オリゴヌクレオチド
  • 肝臓疾患向けRNAiオリゴヌクレオチド

Silence Therapeutics Plc:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Silence Therapeutics Plc:最近のパイプライン動向

Silence Therapeutics Plc:休止中のプロジェクト

Silence Therapeutics Plc:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • Atu-112

Silence Therapeutics Plc:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07563CDB

Summary

Global Markets Direct's, 'Silence Therapeutics plc - Product Pipeline Review - 2015', provides an overview of the Silence Therapeutics plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Silence Therapeutics plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Silence Therapeutics plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Silence Therapeutics plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Silence Therapeutics plc's pipeline products

Reasons to buy

  • Evaluate Silence Therapeutics plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Silence Therapeutics plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Silence Therapeutics plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Silence Therapeutics plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Silence Therapeutics plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Silence Therapeutics plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Silence Therapeutics Plc Snapshot
    • Silence Therapeutics Plc Overview
    • Key Information
    • Key Facts
  • Silence Therapeutics Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Silence Therapeutics Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Silence Therapeutics Plc - Pipeline Products Glance
    • Silence Therapeutics Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Silence Therapeutics Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Silence Therapeutics Plc - Drug Profiles
    • Atu-027
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atu-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atu-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atu-134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Liver Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Silence Therapeutics Plc - Pipeline Analysis
    • Silence Therapeutics Plc - Pipeline Products by Target
    • Silence Therapeutics Plc - Pipeline Products by Route of Administration
    • Silence Therapeutics Plc - Pipeline Products by Molecule Type
    • Silence Therapeutics Plc - Pipeline Products by Mechanism of Action
  • Silence Therapeutics Plc - Recent Pipeline Updates
  • Silence Therapeutics Plc - Dormant Projects
  • Silence Therapeutics Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Atu-112
  • Silence Therapeutics Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Silence Therapeutics Plc, Key Information
  • Silence Therapeutics Plc, Key Facts
  • Silence Therapeutics Plc - Pipeline by Indication, 2015
  • Silence Therapeutics Plc - Pipeline by Stage of Development, 2015
  • Silence Therapeutics Plc - Monotherapy Products in Pipeline, 2015
  • Silence Therapeutics Plc - Partnered Products in Pipeline, 2015
  • Silence Therapeutics Plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Silence Therapeutics Plc - Out-Licensed Products in Pipeline, 2015
  • Silence Therapeutics Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Silence Therapeutics Plc - Phase II, 2015
  • Silence Therapeutics Plc - Preclinical, 2015
  • Silence Therapeutics Plc - Pipeline by Target, 2015
  • Silence Therapeutics Plc - Pipeline by Route of Administration, 2015
  • Silence Therapeutics Plc - Pipeline by Molecule Type, 2015
  • Silence Therapeutics Plc - Pipeline Products by Mechanism of Action, 2015
  • Silence Therapeutics Plc - Recent Pipeline Updates, 2015
  • Silence Therapeutics Plc - Dormant Developmental Projects,2015
  • Silence Therapeutics Plc - Discontinued Pipeline Products, 2015
  • Silence Therapeutics Plc, Other Locations
  • Silence Therapeutics Plc, Subsidiaries

List of Figures

  • Silence Therapeutics Plc - Pipeline by Top 10 Indication, 2015
  • Silence Therapeutics Plc - Pipeline by Stage of Development, 2015
  • Silence Therapeutics Plc - Monotherapy Products in Pipeline, 2015
  • Silence Therapeutics Plc - Partnered Products in Pipeline, 2015
  • Silence Therapeutics Plc - Pipeline by Top 10 Target, 2015
  • Silence Therapeutics Plc - Pipeline by Top 10 Route of Administration, 2015
  • Silence Therapeutics Plc - Pipeline by Top 10 Molecule Type, 2015
  • Silence Therapeutics Plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top